Onconetix (ONCO) Depreciation & Amortization (CF) (2021 - 2026)
Onconetix (ONCO) posted quarterly Depreciation & Amortization (CF) of $5398.0 for Q1 2026, up 13.69% year-over-year from $4748.0 in Q1 2025, and up 61.81% quarter-over-quarter from $3336.0 in Q4 2025.
Onconetix (ONCO) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $5398.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 13.69% year-over-year to $5398.0; the TTM figure through Mar 2026 stood at $15820.0 (down 97.01% YoY), while the FY2025 annual figure was $15170.0, down 97.93% from the prior year.
- Depreciation & Amortization (CF) rose to $5398.0 in Q1 2026 per ONCO's latest filing, from $3336.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $206700.0 in Q1 2024 and bottomed at $1300.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $47211.9 across 5 years, with a median of $3387.0 in 2025.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) jumped 12713.56% — and 2025, when it plunged 98.34%.
- Onconetix's Depreciation & Amortization (CF) stood at $1846.0 in 2022, then jumped by 2015.44% to $39051.0 in 2023, then surged by 205.5% to $119299.0 in 2024, then sank by 97.2% to $3336.0 in 2025, then soared by 61.81% to $5398.0 in 2026.
- Business Quant data shows ONCO's Depreciation & Amortization (CF) at $5398.0 in Q1 2026, $3336.0 in Q4 2025, and $3387.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 2,632.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,632.00 |
| Jun 30, 2026 | 2,632.00 |
| Mar 31, 2026 | 5,398.00 |
| Mar 31, 2026 | 5,398.00 |
| Dec 31, 2025 | 3,336.00 |
| Dec 31, 2025 | 3,336.00 |
| Sep 30, 2025 | 3,387.00 |
| Sep 30, 2025 | 3,387.00 |
| Jun 30, 2025 | 3,699.00 |
| Jun 30, 2025 | 3,699.00 |
| Mar 31, 2025 | 4,748.00 |
| Mar 31, 2025 | 4,748.00 |
| Dec 31, 2024 | 119,299.00 |
| Dec 31, 2024 | 119,299.00 |
| Sep 30, 2024 | 204,045.00 |
| Sep 30, 2024 | 204,045.00 |
| Jun 30, 2024 | 201,301.00 |
| Jun 30, 2024 | 201,301.00 |
| Mar 31, 2024 | 206,700.00 |
| Mar 31, 2024 | 206,700.00 |